Physician profile
Katie E Simkow
NPI 1053770305
$6,158.42
in general payments reported to CMS, 2019-2025
28 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what 86% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,410 · 2022: $1,273 · 2023: $1,331 · 2024: $1,070 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,400 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,400.25 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,251.97 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $867.91 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Abbvie INC. | $866.25 | 2021-2025 | |
| Novo Nordisk INC | $582.57 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $563.23 | 2021-2025 | |
| Glaxosmithkline, LLC. | $511.43 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $234.96 | 2021-2025 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.11 | 2021-2023 | Jardiance |
| Astellas Pharma US INC | $163.93 | 2021-2025 | Veozah |
| Currax Pharmaceuticals LLC | $147.10 | 2023-2024 | Nexletol, Contrave, Nexlizet |
| Exact Sciences Corporation | $119.52 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $76.31 | 2021-2022 | |
| Abbott Laboratories | $71.24 | 2022-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $70.83 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $49.40 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $40.33 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.66 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.53 | 2021-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $36.51 | 2025 | Auvelity |
| Endo Pharmaceuticals INC. | $32.20 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $31.68 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $28.63 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.75 | 2021 | |
| Esperion Therapeutics, INC. | $18.89 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $17.78 | 2024 | Uptravi, Opsumit |
| Sanofi Pasteur INC. | $16.90 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.48 | 2023 | Xarelto |
| Eisai INC. | $15.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Simkow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.